Metabolic · Small molecule (oral, once daily)

Orforglipron (Foundayo)

Orforglipron (Foundayo) is a once-daily oral GLP-1 receptor agonist. The FDA approved it for chronic weight management on April 1, 2026. Its use in type 2 diabetes has been submitted to the FDA and remains investigational.

FDA-approvedFDA-approved for chronic weight management (April 2026); type 2 diabetes submitted in the U.S.

FDA-approved: Approved by the FDA for at least one use. Other uses may still be in clinical trials. About status badges

FDA: approved as FOUNDAYO (NDA220934), original approval Apr 1, 2026. Approval covers specific uses only; see programs below.

DeveloperEli Lilly and Company · Eli Lilly and Company pipeline
Drug typeSmall molecule (oral, once daily)
TargetGLP-1 receptor
MechanismActivates the GLP-1 receptor, reducing appetite and improving blood sugar control
Other namesLY3502970

Key points

  • Orforglipron is a small-molecule pill that activates the GLP-1 receptor, the same target as injectable semaglutide.
  • The FDA approved it as Foundayo on April 1, 2026, for chronic weight management, under its National Priority Voucher pilot. The FDA called it the fastest approval of a new molecular entity since 2002.
  • In the 3,127-patient ATTAIN-1 trial, the 36 mg dose reduced body weight by 11.2% at 72 weeks, compared with 2.1% with placebo.
  • Foundayo's label carries a boxed warning for thyroid C-cell tumors, as with other GLP-1 receptor agonists.
  • Lilly has submitted orforglipron for type 2 diabetes in the U.S. (company-reported). That use is not yet approved.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Obesity and overweight (chronic weight management)
Approved for chronic weight management in adults with obesity, or overweight with weight-related conditions (FDA). Additional obesity-related trials continue.
Approved (FDA, April 1, 2026)24
13 active · 11 completed
Not shown (see note)
Type 2 diabetes
Lilly reported a U.S. submission for type 2 diabetes in August 2026. ACHIEVE Phase 3 trials met their primary endpoints (peer-reviewed for ACHIEVE-1 and ACHIEVE-3).
Submitted (company-reported)11
2 active · 9 completed
90.6% eventual approval
Application → approval: 90.6%
Cardiovascular, peripheral artery disease and other indications
Includes a 7,140-participant cardiovascular outcomes trial and a peripheral artery disease trial (registry).
Phase 34
4 active · 0 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What orforglipron is

Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. Like injectable semaglutide and liraglutide, it activates the receptor for glucagon-like peptide-1, a gut hormone that reduces appetite and improves blood sugar control. Unlike those drugs, orforglipron is a small molecule rather than a peptide. That allows it to be taken as a pill, and Lilly states it can be taken without food or water restrictions (company-reported).

Regulatory status

Use Status
Chronic weight management (adults with obesity, or overweight with weight-related conditions) FDA-approved as Foundayo, April 1, 2026 (NDA 220934)
Type 2 diabetes Submitted in the U.S. (company-reported, August 2026); not yet approved
Cardiovascular outcomes and other conditions In Phase 3 trials

The FDA approved Foundayo under its Commissioner's National Priority Voucher pilot program. In its announcement, the FDA described it as the first new molecular entity approved under the program and the fastest approval of a new molecular entity since 2002, coming 50 days after filing. The label includes a boxed warning for thyroid C-cell tumors, as do other drugs in the class.

Clinical evidence

Obesity: ATTAIN-1

ATTAIN-1 randomized 3,127 adults with obesity, or overweight with a weight-related condition, and no diabetes. Published in the New England Journal of Medicine in 2025, mean changes in body weight at 72 weeks were:

Dose Change in body weight
6 mg −7.5%
12 mg −8.4%
36 mg −11.2%
Placebo −2.1%

On 36 mg, 54.6% of participants lost at least 10% of their body weight, compared with 12.9% on placebo. Adverse events led to discontinuation in 5.3% to 10.3% of orforglipron groups, compared with 2.7% with placebo. The most common adverse events were gastrointestinal and mostly mild to moderate, consistent with other GLP-1 receptor agonists.

Type 2 diabetes: ACHIEVE

In ACHIEVE-1, published in the New England Journal of Medicine in 2025, 559 people with early type 2 diabetes and a mean glycated hemoglobin (HbA1c) of 8.0% were randomized. At 40 weeks, HbA1c fell by 1.24 to 1.48 percentage points with orforglipron, compared with 0.41 with placebo. All doses were superior to placebo. ACHIEVE-3, published in The Lancet in 2026, compared orforglipron with oral semaglutide. Lilly has reported that the ACHIEVE program supported a U.S. submission for type 2 diabetes.

Scientific perspective

Orforglipron's significance is less about magnitude than about format. Its weight loss in ATTAIN-1 is smaller than that reported for injectable tirzepatide or for retatrutide, but a once-daily pill without dosing restrictions could make GLP-1 therapy easier to start, scale, and manufacture. Small molecules are generally simpler to produce at large volumes than peptides.

The key scientific questions now are long-term: cardiovascular outcomes, which a 7,140-participant outcomes trial is testing, and real-world persistence, since daily oral therapy depends on patients continuing to take it.

Development perspective

  • Approved use: chronic weight management. Benchmarks are not shown for this program because it is already approved.
  • Type 2 diabetes: submitted (company-reported). Historically, 90.6% of applications that reached the FDA were eventually approved, often after resubmission. That is an industry-wide figure and not a prediction for this application.
  • Cardiovascular safety: Lilly reported in October 2026 that orforglipron demonstrated cardiovascular safety (company-reported). The detailed results had not been peer-reviewed in the sources we reviewed.
  • Speed of approval: the 50-day review under the National Priority Voucher pilot is unusual. Standard reviews for new molecular entities target about 12 months from submission. See How Does the FDA Approve New Drugs?

Competitive context

Foundayo enters a market led by injectable semaglutide and tirzepatide, and competes with oral semaglutide. Its advantages are convenience and potentially manufacturing scale. Its trade-off, based on published trials, is more modest average weight loss than the leading injectables.

Development timeline

  1. Jun 5, 2023ATTAIN-1 Phase 3 obesity trial begins. Registry
  2. Jun 21, 2025ACHIEVE-1 published: glycated hemoglobin fell by up to 1.48 points at 40 weeks in early type 2 diabetes. Peer-reviewed
  3. Sep 16, 2025ATTAIN-1 published: −11.2% body weight at 72 weeks on 36 mg, versus −2.1% with placebo. Peer-reviewed
  4. Feb 26, 2026ACHIEVE-3 published: orforglipron compared with oral semaglutide in type 2 diabetes. Peer-reviewed
  5. Apr 1, 2026FDA approves Foundayo (orforglipron) for chronic weight management under the National Priority Voucher pilot program. Regulator
  6. Aug 5, 2026Lilly reports a U.S. regulatory submission for orforglipron in type 2 diabetes. Company-reported
  7. Oct 29, 2026Lilly reports that orforglipron demonstrated cardiovascular safety. Company-reported

What could change the outlook

  • The FDA decision on the type 2 diabetes submission.
  • Peer-reviewed publication of the cardiovascular safety results Lilly reported in October 2026.
  • The 7,140-participant cardiovascular outcomes trial, which could support a cardiovascular risk-reduction claim (registry estimates primary completion in August 2031).
  • Real-world tolerability and persistence, since gastrointestinal effects led some trial participants to discontinue.
  • Additional submissions for weight-related conditions, such as obstructive sleep apnea.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Orforglipron. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedOct 29, 2026

    Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

    “Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.

    Source
    SEC Form 8-K · Financial results
  2. Trial resultsCompany-reportedOct 1, 2026

    Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

    Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a...

  3. Trial resultsCompany-reportedSep 30, 2026

    Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

    Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased...

All Orforglipron disclosures in Pipeline News

Clinical trials

53 registered trials list Orforglipron as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Obesity and overweight (chronic weight management)

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07729332
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Phase 4Not yet recruiting60 (est.)Jul 31, 2031 (est.)No
ATTAIN-1 · NCT05869903
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Phase 3Active, not recruiting3,127Jul 25, 2025Yes
ATTAIN-NOW · NCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Phase 3Recruiting2,001 (est.)Aug 2029 (est.)No
ATTAIN-2 · NCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Phase 3Completed1,613Aug 8, 2025Yes
NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Phase 3Active, not recruiting1,400 (est.)Aug 2027 (est.)No
RESTRAIN-SUI · NCT07202884
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Phase 3Recruiting1,000 (est.)Mar 2028 (est.)No
NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Phase 3Active, not recruiting800 (est.)Aug 2027 (est.)No
ATTAIN-OA PAIN · NCT07153471
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Phase 3Active, not recruiting800 (est.)Apr 2028 (est.)No
ATTAIN-OSA · NCT06649045
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Phase 3Completed712Jul 21, 2026No
NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Phase 3Active, not recruiting600 (est.)Aug 2027 (est.)No
NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Phase 3Active, not recruiting487 (est.)Sep 2027 (est.)No
NCT06584916
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Phase 3Completed376Nov 21, 2025No
ATTAIN-J · NCT05931380
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Phase 3Completed238Jun 19, 2025Yes
ATTAIN-CN · NCT07790861
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Phase 3Not yet recruiting192 (est.)Mar 2028 (est.)No
NCT06672939
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3Recruiting150 (est.)Dec 2027 (est.)No
ADVANCE · NCT06672549
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3Recruiting125 (est.)Feb 2027 (est.)No
NCT05051579
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Phase 2Completed272Aug 25, 2022Yes
7 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06440980
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Phase 1Completed533Jun 2, 2025Yes
NCT06824051
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Phase 1Completed120Jan 26, 2026No
NCT07793019
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Phase 1Recruiting104 (est.)Sep 6, 2027 (est.)No
NCT05313802
A Study of LY3502970 in Healthy Overweight and Obese Participants
Phase 1Completed72Sep 9, 2022Yes
NCT05841238
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Phase 1Completed52Sep 14, 2023Yes
NCT06186622
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Phase 1Completed50Jul 10, 2024Yes
NCT06023095
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Phase 1Completed24Jul 29, 2024Yes

Type 2 diabetes

TrialPhaseStatusEnrollmentPrimary completionResults posted
ACHIEVE-4 · NCT05803421
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Phase 3Completed2,749Mar 16, 2026No
ACHIEVE-3 · NCT06045221
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Phase 3Completed1,698Aug 22, 2025Yes
ACHIEVE-2 · NCT06192108
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Phase 3Completed962Sep 26, 2025Yes
ACHIEVE-1 · NCT05971940
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Phase 3Completed559Apr 3, 2025Yes
ACHIEVE-5 · NCT06109311
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Phase 3Completed546Sep 15, 2025Yes
ACHIEVE-J · NCT06010004
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Phase 3Completed401Jun 5, 2025Yes
ACHIEVE-PEDS · NCT07668336
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Phase 3Recruiting170 (est.)Mar 2030 (est.)No
ACHIEVE-RAM · NCT07613307
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Phase 3Recruiting130 (est.)May 2027 (est.)No
NCT05048719
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Phase 2Completed383Sep 30, 2022Yes
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT04426474
A Study of LY3502970 in Participants With Type 2 Diabetes
Phase 1Completed68Jul 12, 2021Yes
NCT05086445
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Phase 1Completed62Sep 5, 2022Yes

Cardiovascular, peripheral artery disease and other indications

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Phase 3Recruiting7,140 (est.)Aug 2031 (est.)No
ATTAIN-PAD · NCT07223593
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Phase 3Recruiting1,205 (est.)Jun 2028 (est.)No
NCT06948422
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Phase 3Active, not recruiting974 (est.)Sep 2027 (est.)No
NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Phase 3Active, not recruiting487 (est.)Sep 2027 (est.)No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
PATHS-T2D · NCT07739537
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Phase 4Not yet recruiting100 (est.)Sep 30, 2029 (est.)No
13 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT03929744
A Study of LY3502970 in Healthy Participants
Phase 1Completed133Nov 2, 2020Yes
NCT06692348
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Phase 1Completed86Jun 9, 2025No
NCT05341089
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Phase 1Completed39Sep 1, 2022Yes
NCT05110794
A Multiple-Dose Study of LY3502970 in Healthy Participants
Phase 1Completed34Feb 10, 2022Yes
NCT05573230
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Phase 1Completed32Jan 17, 2023Yes
NCT06370728
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Phase 1Completed30Jul 23, 2024Yes
NCT05882032
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Phase 1Completed29Nov 18, 2024Yes
NCT06704763
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Phase 1Completed27Feb 5, 2025Yes
NCT05051566
A Multiple Dose Study of LY3502970 in Healthy Participants
Phase 1Completed26Apr 4, 2022Yes
NCT05469126
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Phase 1Completed26Nov 3, 2022Yes
NCT05936138
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
Phase 1Completed24Apr 11, 2024Yes
NCT06085482
A Phase I Study of LY3502970 in Healthy Participants
Phase 1Completed10Jan 5, 2024Yes
NCT04680767
A Study of LY3502970 in Healthy Male Participants
Phase 1Completed6Jul 3, 2021Yes

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (April 1, 2026).Regulator
  2. Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine. 2025;393(18):1796–1806.Peer-reviewed
  3. Rosenstock J, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). New England Journal of Medicine. 2025;393(11):1065–1076.Peer-reviewed
  4. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). The Lancet. 2026;407(10534):1147–1160.Peer-reviewed
  5. Eli Lilly and Company. Form 8-K: Q2 2026 results (August 5, 2026).Company-reported
  6. Eli Lilly and Company. Form 8-K: Q3 2026 results (October 29, 2026).Company-reported
  7. openFDA. Drugs@FDA record for NDA 220934 (Foundayo).Regulator
  8. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.